Low-dose dietary phytoestrogen abrogates tamoxifen-associated mammary tumor prevention

Bolin Liu, Susan Edgerton, Xiaohe Yang, Aeree Kim, Dalia Ordonez-Ercan, Terza Mason, Kathy Alvarez, Christine McKimmey, Naxin Liu, Ann Thor

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

Wild-type erbB-2/neu transgenic mice were used to study the interactions between tamoxifen and dietary phytoestrogens (or isoflavones) by dose and form in vivo. Mice were randomized to one of four dietary formulas and implanted with an 8-week continuous-release tamoxifen or placebo pellet at 8 weeks of age. In placebo-treated mice, soy meal diet (but not diets supplemented with low-dose or high-dose isoflavones or a casein diet) resulted in prolongation of tumor latency. In tamoxifen-treated mice fed the soy meal, casein, or high-dose isoflavone enriched diets, the majority (>80%) showed no tumor formation by 60 weeks of age. Of the mice that developed tumors, latency was significantly prolonged. In tamoxifen-treated mice fed the low-dose isoflavone enriched diet, a much higher rate of mammary tumor development (>50%; P < 0.002) and a shorter tumor latency were observed. In vitro studies of human and mouse mammary tumor cell lines confirm that low doses of genistein, co-administered with tamoxifen, promote cell proliferation. This is in contrast to tamoxifen alone or tamoxifen with higher doses of genistein that are growth inhibitory. In summary, low-dose dietary isoflavones abrogated tamoxifen-associated mammary tumor prevention in vivo. These interactions are supported by in vitro data from human and mouse mammary tumor cell lines. These dose-associated interactions likely have relevance to the human use of tamoxifen for prevention or treatment of breast cancer.

Original languageEnglish
Pages (from-to)879-886
Number of pages8
JournalCancer Research
Volume65
Issue number3
Publication statusPublished - 2005 Feb 1
Externally publishedYes

Fingerprint

Phytoestrogens
Tamoxifen
Breast Neoplasms
Isoflavones
Diet
Genistein
Caseins
Tumor Cell Line
Meals
Neoplasms
Placebos
Transgenic Mice
Cell Proliferation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Liu, B., Edgerton, S., Yang, X., Kim, A., Ordonez-Ercan, D., Mason, T., ... Thor, A. (2005). Low-dose dietary phytoestrogen abrogates tamoxifen-associated mammary tumor prevention. Cancer Research, 65(3), 879-886.

Low-dose dietary phytoestrogen abrogates tamoxifen-associated mammary tumor prevention. / Liu, Bolin; Edgerton, Susan; Yang, Xiaohe; Kim, Aeree; Ordonez-Ercan, Dalia; Mason, Terza; Alvarez, Kathy; McKimmey, Christine; Liu, Naxin; Thor, Ann.

In: Cancer Research, Vol. 65, No. 3, 01.02.2005, p. 879-886.

Research output: Contribution to journalArticle

Liu, B, Edgerton, S, Yang, X, Kim, A, Ordonez-Ercan, D, Mason, T, Alvarez, K, McKimmey, C, Liu, N & Thor, A 2005, 'Low-dose dietary phytoestrogen abrogates tamoxifen-associated mammary tumor prevention', Cancer Research, vol. 65, no. 3, pp. 879-886.
Liu B, Edgerton S, Yang X, Kim A, Ordonez-Ercan D, Mason T et al. Low-dose dietary phytoestrogen abrogates tamoxifen-associated mammary tumor prevention. Cancer Research. 2005 Feb 1;65(3):879-886.
Liu, Bolin ; Edgerton, Susan ; Yang, Xiaohe ; Kim, Aeree ; Ordonez-Ercan, Dalia ; Mason, Terza ; Alvarez, Kathy ; McKimmey, Christine ; Liu, Naxin ; Thor, Ann. / Low-dose dietary phytoestrogen abrogates tamoxifen-associated mammary tumor prevention. In: Cancer Research. 2005 ; Vol. 65, No. 3. pp. 879-886.
@article{b3e1f1aacd194f7bb89ae4cd9f050b9c,
title = "Low-dose dietary phytoestrogen abrogates tamoxifen-associated mammary tumor prevention",
abstract = "Wild-type erbB-2/neu transgenic mice were used to study the interactions between tamoxifen and dietary phytoestrogens (or isoflavones) by dose and form in vivo. Mice were randomized to one of four dietary formulas and implanted with an 8-week continuous-release tamoxifen or placebo pellet at 8 weeks of age. In placebo-treated mice, soy meal diet (but not diets supplemented with low-dose or high-dose isoflavones or a casein diet) resulted in prolongation of tumor latency. In tamoxifen-treated mice fed the soy meal, casein, or high-dose isoflavone enriched diets, the majority (>80{\%}) showed no tumor formation by 60 weeks of age. Of the mice that developed tumors, latency was significantly prolonged. In tamoxifen-treated mice fed the low-dose isoflavone enriched diet, a much higher rate of mammary tumor development (>50{\%}; P < 0.002) and a shorter tumor latency were observed. In vitro studies of human and mouse mammary tumor cell lines confirm that low doses of genistein, co-administered with tamoxifen, promote cell proliferation. This is in contrast to tamoxifen alone or tamoxifen with higher doses of genistein that are growth inhibitory. In summary, low-dose dietary isoflavones abrogated tamoxifen-associated mammary tumor prevention in vivo. These interactions are supported by in vitro data from human and mouse mammary tumor cell lines. These dose-associated interactions likely have relevance to the human use of tamoxifen for prevention or treatment of breast cancer.",
author = "Bolin Liu and Susan Edgerton and Xiaohe Yang and Aeree Kim and Dalia Ordonez-Ercan and Terza Mason and Kathy Alvarez and Christine McKimmey and Naxin Liu and Ann Thor",
year = "2005",
month = "2",
day = "1",
language = "English",
volume = "65",
pages = "879--886",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Low-dose dietary phytoestrogen abrogates tamoxifen-associated mammary tumor prevention

AU - Liu, Bolin

AU - Edgerton, Susan

AU - Yang, Xiaohe

AU - Kim, Aeree

AU - Ordonez-Ercan, Dalia

AU - Mason, Terza

AU - Alvarez, Kathy

AU - McKimmey, Christine

AU - Liu, Naxin

AU - Thor, Ann

PY - 2005/2/1

Y1 - 2005/2/1

N2 - Wild-type erbB-2/neu transgenic mice were used to study the interactions between tamoxifen and dietary phytoestrogens (or isoflavones) by dose and form in vivo. Mice were randomized to one of four dietary formulas and implanted with an 8-week continuous-release tamoxifen or placebo pellet at 8 weeks of age. In placebo-treated mice, soy meal diet (but not diets supplemented with low-dose or high-dose isoflavones or a casein diet) resulted in prolongation of tumor latency. In tamoxifen-treated mice fed the soy meal, casein, or high-dose isoflavone enriched diets, the majority (>80%) showed no tumor formation by 60 weeks of age. Of the mice that developed tumors, latency was significantly prolonged. In tamoxifen-treated mice fed the low-dose isoflavone enriched diet, a much higher rate of mammary tumor development (>50%; P < 0.002) and a shorter tumor latency were observed. In vitro studies of human and mouse mammary tumor cell lines confirm that low doses of genistein, co-administered with tamoxifen, promote cell proliferation. This is in contrast to tamoxifen alone or tamoxifen with higher doses of genistein that are growth inhibitory. In summary, low-dose dietary isoflavones abrogated tamoxifen-associated mammary tumor prevention in vivo. These interactions are supported by in vitro data from human and mouse mammary tumor cell lines. These dose-associated interactions likely have relevance to the human use of tamoxifen for prevention or treatment of breast cancer.

AB - Wild-type erbB-2/neu transgenic mice were used to study the interactions between tamoxifen and dietary phytoestrogens (or isoflavones) by dose and form in vivo. Mice were randomized to one of four dietary formulas and implanted with an 8-week continuous-release tamoxifen or placebo pellet at 8 weeks of age. In placebo-treated mice, soy meal diet (but not diets supplemented with low-dose or high-dose isoflavones or a casein diet) resulted in prolongation of tumor latency. In tamoxifen-treated mice fed the soy meal, casein, or high-dose isoflavone enriched diets, the majority (>80%) showed no tumor formation by 60 weeks of age. Of the mice that developed tumors, latency was significantly prolonged. In tamoxifen-treated mice fed the low-dose isoflavone enriched diet, a much higher rate of mammary tumor development (>50%; P < 0.002) and a shorter tumor latency were observed. In vitro studies of human and mouse mammary tumor cell lines confirm that low doses of genistein, co-administered with tamoxifen, promote cell proliferation. This is in contrast to tamoxifen alone or tamoxifen with higher doses of genistein that are growth inhibitory. In summary, low-dose dietary isoflavones abrogated tamoxifen-associated mammary tumor prevention in vivo. These interactions are supported by in vitro data from human and mouse mammary tumor cell lines. These dose-associated interactions likely have relevance to the human use of tamoxifen for prevention or treatment of breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=13444252334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13444252334&partnerID=8YFLogxK

M3 - Article

VL - 65

SP - 879

EP - 886

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 3

ER -